Skip to main content
AVECHO BIOTECHNOLOGY LIMITED logo

AVECHO BIOTECHNOLOGY LIMITED — Investor Relations & Filings

Ticker · AVE ISIN · AU0000047441 LEI · 529900FA9G9T82C2LV25 ASX Manufacturing
Open in API
Filings indexed 881 across all filing types
Latest filing 2023-04-02 Capital/Financing Update
Country AU Australia
Listing ASX AVE

About AVECHO BIOTECHNOLOGY LIMITED

https://avecho.com.au/

Avecho Biotechnology Limited develops and commercializes human and animal health products using its proprietary drug delivery system, Tocopheryl Phosphate Mixture (TPM®). Derived from Vitamin E, TPM® is designed to enhance the solubility and absorption of active ingredients through the skin and digestive tract. The company focuses on applying this technology to pharmaceuticals, nutraceuticals, and animal health sectors. A primary area of development includes medicinal cannabis, where Avecho has produced high-bioavailability cannabidiol (CBD) softgel capsules for therapeutic use. The company’s portfolio also includes applications in pain management and dermatology, leveraging TPM® to improve the delivery of poorly soluble molecules and enhance the efficacy of existing treatments.

Recent filings

Filing Released Lang Actions
Entitlement Offer to raise $11m for Phase 3 clinical trial 4 pages 192.6KB
Capital/Financing Update Classification · 100% confidence The document is an ASX release dated 3 April 2023 from Avecho Biotechnology Limited announcing a capital raising via an entitlement offer to raise approximately A$11 million. The purpose of the raise is to fund a Phase III clinical trial. The document details the terms of the entitlement offer, including the issue price, record date, and use of funds. It also includes information about an investor webinar and key dates related to the offer. There are no financial statements or detailed financial performance data presented. The document is primarily an announcement of a financing activity (capital raising) and not a full financial report or earnings release. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2023-04-02 English
Prospectus 37 pages 510.9KB
Capital/Financing Update Classification · 100% confidence The document is titled 'Prospectus' and describes a pro rata non-renounceable offer of new shares and options to raise capital, including detailed terms of the entitlement offer, risk factors, application instructions, and legal notices. It is a transaction-specific prospectus issued under section 713 of the Corporations Act 2001 (Cth), which is typical for capital raising documents. The content focuses on the offer of securities, subscription details, and related corporate actions rather than financial results or management commentary. This matches the definition of a Capital/Financing Update (CAP), which covers updates on company fundraising and financing activities. The document is not an annual or interim report, earnings release, or regulatory filing, but a detailed prospectus for a capital raising event.
2023-04-02 English
Investor Presentation 32 pages 1.8MB
Investor Presentation Classification · 95% confidence The document is a detailed presentation by Avecho Biotechnology Limited regarding a pro rata non-renounceable entitlement offer to fund a pivotal Phase III clinical trial. It includes disclaimers, company background, strategic focus, product information, market overview, and clinical trial plans. The content is structured as a presentation aimed at investors, focusing on financial and strategic information related to the entitlement offer and the company's development pipeline. There is no indication that this is a full financial report, audit report, or regulatory filing. It is not a transcript of a call, nor a voting result or dividend notice. The document is clearly an investor presentation, as it provides detailed information on the company's strategy, market, and financing plans to attract investment. Therefore, the appropriate classification is Investor Presentation (IP). The document length (15,000 characters) and content support this classification with high confidence.
2023-04-02 English
Proposed issue of securities - AVE 13 pages 48.3KB
Capital/Financing Update Classification · 100% confidence The document is a detailed announcement regarding a proposed issue of securities by Avecho Biotechnology Limited. It includes specifics such as the types and quantities of securities to be issued, offer prices, record dates, issue dates, and conditions related to the securities offering. The content focuses on the company's capital raising activities through a pro rata issue and placement of new shares and options. There is no indication that this is a full financial report, audit report, earnings release, or any other type of report. Instead, it is clearly an update on the company's capital structure and fundraising plans. Therefore, the document fits the category of Capital/Financing Update (CAP). The document length and detail support a high confidence in this classification.
2023-04-02 English
Target Market Determination 8 pages 143.5KB
Regulatory Filings Classification · 95% confidence The document is titled 'Target Market Determination' and relates to offers of options connected with an entitlement offer under a prospectus dated 3 April 2023. It details the target market for these financial products, the suitability of the offers for different investor types, distribution conditions, review triggers, and reporting requirements. The document is regulatory in nature, focusing on compliance with financial product distribution laws and investor protections, rather than presenting financial results, management commentary, or corporate governance changes. It does not contain financial statements or earnings data, nor is it a report of voting results or a proxy statement. It is not a notice of dividend, capital change, or share transaction. The document is a regulatory compliance disclosure related to the distribution of financial products and is not a full financial report or announcement of a report. Therefore, it fits best under the category of Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory compliance documents that do not fit other categories.
2023-04-02 English
Letter to Optionholders 2 pages 46.1KB
Capital/Financing Update Classification · 100% confidence The document is a letter dated 3 April 2023 from Avecho Biotechnology Limited addressed to optionholders. It announces a non-renounceable entitlement offer to raise capital by issuing new shares and attaching options. The letter explains the terms of the entitlement offer, eligibility, and participation instructions. It references a prospectus and provides contact information for further inquiries. The content focuses on a fundraising activity involving share issuance and options, which is a capital raising event. The document is not a full financial report, earnings release, or regulatory filing but an update on a financing activity. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length is 5345 characters, sufficient to contain substantive information about the capital raising event rather than a brief announcement or report publication notice.
2023-04-02 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.